ProBiotix Health is facing a significant leadership crisis as a primary shareholder demands the CEO’s resignation.
- The shareholder, Seneca Partners, holds a 5.5% stake and has called for a vote to remove the CEO and a non-executive director.
- ProBiotix’s board has rejected the proposal, deeming it highly disruptive and unnecessary.
- The dispute follows ProBiotix’s unsuccessful attempt to raise capital, leading them to secure investment under specific conditions.
- This ongoing conflict is occurring at a pivotal moment in ProBiotix’s growth trajectory.
ProBiotix Health, a firm in the life sciences sector, has encountered a major crisis in its leadership structure. This turmoil was sparked by Seneca Partners, a significant shareholder with a 5.5% stake, who has officially called for the resignation of CEO Steen Andersen. Additionally, a non-executive director affiliated with a major investor is also targeted for removal in this requisition.
The board of ProBiotix Health has strongly opposed these proposals, describing them as ‘hugely disruptive’. The board believes that the resolutions would not only damage existing customer relationships but also result in expenses that are disproportionate and unnecessary at this stage.
The board further argues that these resolutions come at a crucial moment for ProBiotix as the company is gaining commercial traction. The board maintains that the CEO has carried out his role with professionalism and that his position had not previously warranted any form of disciplinary action.
This conflict follows ProBiotix’s earlier financial challenges when it approached shareholders for a fresh injection of capital. Despite their efforts, Seneca Partners and others rejected this plea. In response, ProBiotix engaged with Danish entrepreneur Frederik Bruhn-Petersen, securing a £1.2 million share subscription under terms that have since become contentious.
The friction arises from the condition attached to this investment: that Frederik Bruhn-Petersen’s son be appointed as a non-executive director, a move that Seneca has contested. ProBiotix justified this decision by emphasising the value of having a supportive shareholder whose long-term focus can secure the company’s financial foundation.
The leadership crisis at ProBiotix Health underscores the complex dynamics between financial strategy and corporate governance during critical growth phases.
